Puromycin aminonucleoside
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: N/A
Puromycin aminonucleoside,3'-氨基-3'-脱氧-N6,N6-二甲基腺苷,是抗生素嘌呤霉素的氨基核苷部分。Puromycin aminonucleoside(PAN)诱导的大鼠肾病为调查严重蛋白尿病情的发病机制提供了模型。
体外:一项前期研究使用扫描(SEM)和透射(TEM)电子显微镜检验PAN对大鼠肾小球足细胞的体外作用。大鼠肾脏切片与PAN孵育,肾脏切片上肾小球的SEM分析表明,PAN孵育降低足细胞细胞体上微绒毛的数目并增加肾小球的数量。TEM形态显示,PAN孵育显著延缓对照组观察到的足细胞足突的损失[1]。
体内:在Wistar大鼠中,多次注射PAN导致持续重度蛋白尿和肾小球FSGHS病变。在PVG/c大鼠中,诱导慢性蛋白尿需要更高剂量的PAN。在单次静脉注射PAN引起的急性PAN肾病的Wistar大鼠中,系膜出现大量脂质,而肾病PVG/c大鼠仅出现较小的系膜脂滴。此外,与无蛋白尿对照组相比,肾病PVG/c大鼠注射胶体炭后,系膜未发现炭累积增加[2]。
临床试验:N/A
参考文献:
[1] Grond J,μMuller EW,van Goor H,Weening JJ,Elema JD. Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int.1988 Feb;33(2):524-9.
[2] Bertram JF,μMessina A,Ryan GB. In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes. Cell Tissue Res.1990 May;260(3):555-63.
Storage | Store at -20°C |
M.Wt | 294.31 |
Cas No. | 58-60-6 |
Formula | C12H18N6O3 |
Synonyms | 3'-Amino-3'-deoxy-N6,N6-dimethyladenosine |
Solubility | ≥14.45 mg/mL in DMSO; ≥29.4 mg/mL in EtOH with gentle warming; ≥29.5 mg/mL in H2O with gentle warming |
Chemical Name | 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol |
SDF | Download SDF |
Canonical SMILES | CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
Madin-Darby犬肾(MDCK)细胞 |
溶解方法 |
该化合物在DMSO中的溶解度大于14.5 mg/mL。若获取更高浓度的溶液,可在37℃下孵育10分钟,随后在超声波浴中摇匀。-20℃以下可储存数月。 |
反应条件 |
48 h |
应用 |
在载体和PMAT转染的MDCK细胞中,Puromycin aminonucleoside(PAN)显示细胞毒性,IC50值分别为48.9 ± 2.8和122.1 ± 14.5 μM。PAN(250 μM)对表达PMAT和载体转染细胞均有毒性。在pH 6.6时,PMAT表达细胞中的Puromycin aminonucleoside摄取比pH 7.4条件下高4倍。 |
动物实验 [2,3]: | |
动物模型 |
肾病大鼠 |
给药剂量 |
静脉注射,60 mg/kg,150 mg/kg |
应用 |
在肾病大鼠中,静脉注射PAN (8 mg/100 g),在第4天,每个肾小球的足细胞数为90.7。 PAN治疗的肾病大鼠中,每只小鼠肾小球的肾素量在第4天和第7天分别降至0.46 ± 0.06 fmol及0.35 ± 0.04 fmol。在Puromycin aminonucleoside治疗的肾病大鼠中,每个足细胞的肾素量显著降低,与蛋白尿的发生有关。皮下给药PAN(100 mg/kg)的大鼠体重减轻,血清肌酐水平高于对照组,表明Puromycin aminonucleoside损伤肾功能。 |
注意事项 |
由于实验环境的不同,实际溶解度可能与理论值略有不同,请测试室内所有化合物的溶解度。 |
References: [1]. Xia L, Zhou M, Kalhorn T F, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. American Journal of Physiology-Renal Physiology, 2009, 296(6): F1307-F1313. [2]. Kawakami, Hirotaka, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrology Dialysis Transplantation 27.4 (2011): 1324-1330. [3]. Nosaka, Kazuo, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radical Biology and Medicine 22.4 (1997): 597-605. |
质量控制和MSDS
- 批次: